You are here

Press Releases

LAS VEGAS, June 20, 2016 /PRNewswire/ -- Nevada Heart and Vascular Center is proud to congratulate Chowdhury H. Ahsan, M.D., F.A.C.C. F.S.C.A.I. for his recent election to Alpha Omega Alpha, the medical honor society. This honor was awarded by medical students, residents and faculty members from University of Nevada School of Medicine to recognize Dr. Ahsan's academic excellence, dedication to medicine as a profession, and service to patients. Dr. Ahsan received this prestigious award as result of his work as director of the Cardiology Fellowship program at the university.

COLUMBIA, Mo. (June 15, 2016) ― As men and women grow older, their chances for coronary heart disease also increase. Atherosclerosis is a condition in which plaque builds up inside the arteries, which can lead to serious problems, including heart attacks, strokes or even death. Now, researchers at the University of Missouri have found that Insulin-like Growth Factor-1 (IGF-1), a protein that is naturally found in high levels among adolescents, can help prevent arteries from clogging. They say that increasing atherosclerosis patients’ levels of the protein could reduce the amount of plaque buildup in their arteries, lowering their risk of heart disease.

SAN RAMON, Calif., June 16, 2016 (GLOBE NEWSWIRE) -- SteadyMed Ltd. (Nasdaq:STDY), a specialty pharmaceutical company focused on the development of drug product candidates to treat orphan and high-value diseases with unmet parenteral delivery needs, today announced that it has launched the PHenomenal campaign, which gives people with PH and their loved ones the opportunity to submit photos and videos of themselves showing what makes them interesting and inspiring. To learn more about PH and the PHenomenal campaign, please visit www.youtube.com/user/phenomself.

DUBLIN and NEW ORLEANS - June 10, 2016 - Delivering on its vision to transform care for the millions currently living with diabetes through intelligent data, Medtronic plc (NYSE:MDT) announced new product developments and technology partnerships at the American Diabetes Association (ADA) 76th Scientific Sessions that will create meaningful insights for providers and people with diabetes. 

June 10, 2016—CHELMSFORD, MASS.—ZOLL®Medical Corporation, an Asahi Kasei Group Company that manufactures medical devices and related software solutions, announced that patients experience a high one-year survival rate following use of the LifeVest® Wearable Defibrillator. New results from the Prospective Registry of Patients Using the Wearable Defibrillator (WEARIT-II Registry) were presented today by Valentina Kutyifa, MD, PhD, University of Rochester Medical Center, during the Late-Breaking Clinical Trials session at CARDIOSTIM/EUROPACE 2016.

(PresseBox) BIOTRONIK Home Monitoring® received strong endorsements during the Cardiostim scientific session “Improving Patient Outcomes in Arrhythmia Management.” 

DUBLIN and NICE, FRANCE - JUNE 9, 2016 - Medtronic plc (NYSE:MDT) today announced new results from the Medtronic Micra® Transcatheter Pacing System (TPS) Global Clinical Trial in a late-breaking trial session at CARDIOSTIM / EHRA EUROPACE 2016, the World Congress in Electrophysiology and Cardiac Techniques, in Nice, France. 

DUBLIN and NICE, FRANCE - JUNE 8, 2016 - Medtronic plc (NSYE: MDT) today announced results from several feasibility studies evaluating a new approach to implantable cardioverter defibrillator (ICD) therapy at CARDIOSTIM / EHRA EUROPACE 2016, the World Congress in Electrophysiology and Cardiac Techniques, in Nice, France.

IRVINE, Calif., June 08, 2016 (GLOBE NEWSWIRE) -- Lombard Medical, Inc. (NASDAQ:EVAR), a medical device company focused on Endovascular Aneurysm Repair (EVAR) of abdominal aortic aneurysms (AAAs), today announced the following commercial update of the new Altura® Endovascular Stent Graft System.

A new report published by Allied Market Research titled, World Congestive Heart Failure (CHF) Treatment Devices Market - Opportunities and Forecasts, 2015 -2022, projects that the world CHF treatment devices market would reach $14.8 billion by 2022, at a CAGR of 5.5% from 2016 to 2022. Implantable cardioverter-defibrillator (ICDs) segment is expected to dominate the world CHF treatment devices market throughout the forecast period. North America is projected to continue its lead in terms of revenue, accounting for more than two-fifths share of the world CHF treatment devices.

FLAGSTAFF, Ariz.--()--W. L. Gore & Associates, Inc. (Gore) today announced completion of enrollment into its early feasibility study evaluating the GORE® EXCLUDER® Thoracoabdominal Branch Endoprosthesis (TAMBE) for the treatment of aortic aneurysms involving the visceral branch vessels. The TAMBE is designed to be the first complete off-the-shelf solution for the treatment of this complex disease. The device adds to Gore’s comprehensive portfolio of aortic branch solutions designed to effectively treat aortic aneurysms through minimally invasive means.

June 2, 2016—CHELMSFORD, MASS.—ZOLL® Medical Corporation, an Asahi Kasei Group Company that manufactures medical devices and related software solutions, announced today that Valentina Kutyifa, MD, PhD, University of Rochester Medical Center will present, “One-Year Follow-Up of the Prospective Registry of Patients Using the Wearable Defibrillator (WEARIT-II Registry)” during the Late-Breaking Clinical Trials session at CARDIOSTIM/EUROPACE 2016 in Nice, France on Friday, 10 June, 09:00, Room 1.4–Level 1/Méditerranée, Session #168-01.

Amsterdam, the Netherlands and Tampere, Finland – Royal Philips (NYSE: PHG, AEX: PHIA) today announced that it has signed a strategic partnership agreement with Heart Hospital in Tampere, Finland, to jointly innovate in cardiac care and further reinforce Heart Hospital as a European center of excellence for heart treatment. The multi-year agreement has a value of approximately EUR 19 million, and is the first strategic partnership awarded to Philips in Finland and the third in the Nordic region.
 

(NEW ORLEANS) — Dr. Vinod Nair, President and Chief Software Architect of Objective Medical Systems (OMS), and Dr. Peter Fail, Chief Privacy Officer, have been selected as New Orleans CityBusiness Health Care Heroes for 2016, placing them among the top medical professionals in the Greater New Orleans area.

BALTIMORE, May 17, 2016 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, today announced positive clinical trial results on two of its advanced innovations in surgical heart valves for the treatment of people with aortic valve disease. Data from three studies—COMMENCE, TRANSFORM and FOUNDATION—were presented as part of the late-breaking sessions at the American Association for Thoracic Surgery's (AATS) 96th annual meeting.  

12-month follow-up data on bioabsorbable technology presented today at annual meeting of American Association for Thoracic Surgery.

IRVINE, Calif., May 16, 2016 (GLOBE NEWSWIRE) -- Endologix, Inc. (Nasdaq:ELGX), developer and marketer of innovative treatments for aortic disorders, announced today that it has completed patient enrollment in the LIFE study, a multi-center post-market registry designed to evaluate the Ovation ® Abdominal Stent Graft Platform when used in the treatment of patients with abdominal aortic aneurysms ("AAA") using a Fast-Track EVAR protocol. 

WINNIPEGMay 11, 2016 /CNW/ - Medicure Inc. ("Medicure" or the "Company") (TSXV:MPH, OTC:MCUJF), a specialty pharmaceutical company, is pleased to announce that it has submitted an application to the U.S. Food and Drug Administration (FDA) for the introduction of a new "bolus vial" product format for AGGRASTAT (tirofiban HCl).  

This study builds on the growing body of evidence for managing heart failure using the St. Jude Medical MultiPoint pacing technology for patients not responsive to other therapy options

DUBLIN and SAN FRANCISCO - May 5, 2016 - Medtronic plc (NYSE:MDT) today announced clinical results highlighting the strong safety and performance profile of the miniaturized Micra® Transcatheter Pacing System (TPS) at Heart Rhythm 2016, the Heart Rhythm Society's 37th Annual Scientific Sessions in San Francisco.

Pages